Neovacs Valuation

Is ALNEV undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ALNEV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ALNEV's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ALNEV's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ALNEV?

Key metric: As ALNEV is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for ALNEV. This is calculated by dividing ALNEV's market cap by their current revenue.
What is ALNEV's PS Ratio?
PS Ratio	0.002x
Sales	€823.43k
Market Cap	€1.87k

ALNEV key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.3x
Enterprise Value/EBITDA	-0.04x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does ALNEV's PS Ratio compare to its peers?

The above table shows the PS ratio for ALNEV vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	0.2x
ALPHA Pharnext S.C.A	0.0002x	n/a	€34.0
ALVET TheraVet	0.3x	n/a	€285.5k
VBIV.Q VBI Vaccines	0.002x	n/a	US$14.3k
GV Genomic Vision Société Anonyme	0.4x	n/a	€692.9k
ALNEV Neovacs	0.002x	n/a	€1.9k

Price-To-Sales vs Peers: ALNEV is good value based on its Price-To-Sales Ratio (0x) compared to the peer average (0.2x).

Price to Sales Ratio vs Industry

How does ALNEV's PS Ratio compare vs other companies in the FR Biotechs Industry?

7 Companies	Price / Sales	Estimated Growth	Market Cap
Industry Avg.	3.7x	31.7%
ALNEV Neovacs	0.002x	n/a	US$1.94k
ALGEN genOway Société anonyme	1.2x	n/a	US$35.28m
LYS Lysogene	0.4x	n/a	US$5.42m

7 Companies		Estimated Growth	Market Cap
Industry Avg.	3.7x	4.6%
ALNEV Neovacs	0.002x	n/a	US$1.94k

No more companies

Price-To-Sales vs Industry: ALNEV is good value based on its Price-To-Sales Ratio (0x) compared to the French Biotechs industry average (3.7x).

Price to Sales Ratio vs Fair Ratio

What is ALNEV's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ALNEV PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.002x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate ALNEV's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Sanofi

€116.8b

A healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally.

SAN

€93.17

2.0%

7.9%

Theranexus Société Anonyme

€3.9m

A biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders.

ALTHX

€0.50

-57.2%

Eurofins Scientific

€8.9b

Provides various analytical testing and laboratory services worldwide.

ERF

€46.96

3.3%

-12.0%